Genmab's Epcoritamab Trial Falls Short on Key Survival Metric
Genmab's Phase 3 trial for epcoritamab shows mixed results in lymphoma patients, missing its overall survival goal despite some improvements.
/ 3 items
#GMAB↓
Genmab Stops Development of Acasunlimab to Focus on Key Cancer Treatments
Genmab discontinues acasunlimab development to prioritize high-impact cancer therapies including EPKINLY, petosemtamab, and Rina-S in its late-stage pipeline.
Genmab's $8 Billion Move: Acquiring Merus to Lead the Next Wave of Cancer Antibody Therapeutics
Denmark's Genmab is acquiring Dutch drugmaker Merus for $8 billion to secure petosemtamab, a late-stage, breakthrough treatment for head and neck cancer, bolstering Genmab's proprietary oncology pipeline and accelerating its evolution into a global biotechnology leader.